Indian-origin scientist finds new way to develop better drugs

Image
Press Trust of India Washington
Last Updated : Aug 26 2014 | 4:05 PM IST
An Indian-origin researcher has figured out how biomolecules, which holds sugars in the body like scaffolds for reacting with other molecules, can lead to new and better drugs.
The study focused on a certain type of biomolecule built like a nano-Christmas tree. Called a glycoconjugate, it's many branches are bedecked with sugary ornaments.
According to conventional wisdom, the glycoconjugate's lowly "tree" basically holds the sugars in place as they do the important work of reacting with other molecules.
Now, Tarun Dama, a biochemist at Michigan Technological University has discovered that the tree itself - called the scaffold - is a good deal more than a simple prop.
"We had always thought that all the biological function resides in the sugar," said Dam, principal investigator of the Mechanistic Glycobiology Lab at Michigan Tech.
"People didn't appreciate that the scaffolds were active," said Dam.
The discovery opens up new avenues for research, in particular the development of more and better pharmaceuticals.
Glycoconjugates are found naturally in the body, but they are also an important class of drugs that includes anything from cancer treatments to vaccines.
To determine if the scaffold had a role to play in biological reactions, Dam and his team built and tested two types of glycoconjugate molecules.
They had the same sugars and virtually identical shapes but were comprised of different scaffolds, one made of protein, the other a synthetic.
The scientists then tested how the different glycoconjugates reacted with biomolecules called lectins.
Lectins play an important role in numerous biological processes and are a target for many glycoconjugate drugs.
If the scaffolds had been inert, the reactions would have been identical. However, the sugars on the protein scaffold reacted with the lectins differently.
"If the scaffolds are different, they can cause my drug to work one way and your drug to work another way, even though they have similar epitopes (sugars)," Dam said.
"Tweaking the scaffold can change the drug's function," said Dam.
The research was published in the journal Biochemistry.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 26 2014 | 4:05 PM IST

Next Story